满￥6666，赠豪华版黑神话悟空
Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
囊泡 肿瘤
/
细胞凋亡
帕金森与阿尔茨海默症 肿瘤生长增殖和凋亡
/
凋亡
Bcl-2
/ Venetoclax

维奈妥拉 /Venetoclax 99%

货号：A156386 同义名： ABT-199;GDC-0199 Ambeed 开学季，买赠积分，赢豪礼

Venetoclax (ABT-199; GDC-0199) 是一种高效、选择性且口服有效的 Bcl-2 抑制剂，Ki 小于 0.01 nM。Venetoclax 可以诱导自噬 (autophagy) 作用。

Venetoclax 化学结构 CAS号：1257044-40-8
Venetoclax 化学结构
CAS号：1257044-40-8
Venetoclax 3D分子结构
CAS号：1257044-40-8
Venetoclax 化学结构 CAS号：1257044-40-8
Venetoclax 3D分子结构 CAS号：1257044-40-8
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Venetoclax 纯度/质量文件 产品仅供科研

货号：A156386 标准纯度： 99%
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Cell,2024. Ambeed. [ A125712 ]
• Cancer Discov., 2024. Ambeed. [ A285925 ]
• JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]
• JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]
• EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]
更多 >
产品名称 Bax ↓ Bcl-2 ↓ Bcl-B ↓ Bcl-w ↓ Bcl-xL ↓ Bfl-1 ↓ Mcl-1 ↓ 其他靶点 纯度
BTSA1 ✔ 99%+
HA14-1 +

Bcl-2, IC50: 9 μM

 		98%
Venetoclax ++++

Bcl-2, Ki: <0.01 nM

 		99%
Navitoclax 99%+
Obatoclax Mesylate +++

Bcl-2, Ki: 0.22 μM

 		98%
ABT-737 +++

Bcl-2, EC50: 30.3 nM

 		+

Bcl-B, EC50: 1.82 μM

 		+++

Bcl-w, EC50: 197.8 nM

 		+++

Bcl-xL, EC50: 78.7 nM

 		99%+
Gambogic Acid +

Bcl-2, IC50: 1.21 μM

Bfl-1, IC50: 1.06 μM

 		++

Bcl-B, IC50: 0.66 μM

 		++++

Bcl-w, IC50: 0.02 μM

 		+

Bcl-xL, IC50: 1.47 μM

 		+

Bfl-1, IC50: 1.06 μM

 		++

Mcl-1, IC50: 0.79 μM

 		Caspase 99% HPLC
BH3I-1 +

BH3-Bcl-xL interaction, Ki: 2.4 μM

 		98%
A-1331852 ++++

Bcl-xL, Ki: <0.01 nM

 		99%+
A-1210477 ++++

MCL-1, IC50: 26.2 nM

 		99%+
Maritoclax ✔ 97%
TW-37 +++

Bcl-2, Ki: 0.29 μM

 		+

Bcl-xL, Ki: 1.11 μM

 		+++

Mcl-1, Ki: 0.26 μM

 		98%
UMI-77 ++

Mcl-1, Ki: 490 nM

 		97%
(R)-(-)-Gossypol acetic acid ++

Bcl-2, Ki: 0.32 μM

 		++

Bcl-xL, Ki: 0.48 μM

 		+++

Mcl-1, Ki: 0.18 μM

 		98%
Sabutoclax ++

Bcl-2, IC50: 0.32 μM

Bfl-1, IC50: 0.62 μM

 		++

Bcl-xL, IC50: 0.31 μM

 		++

Bfl-1, IC50: 0.62 μM

 		+++

Mcl-1, IC50: 0.20 μM

 		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Venetoclax 生物活性

靶点

  • Bcl-2

    Bcl-2, Ki:<0.01 nM
描述 Bcl-2 (B-cell lymphoma 2) is the first identified apoptotic regulator. It belongs to Bcl-2 family commitment to PCD, which regulates apoptosis, pro-apoptosis or anti-apoptosis. ABT-199 is a highly potent inhibitor of Bcl-2, re-engineered from ABT-263. It has subnanomolar affinity (Ki<0.010 nM, analysis by TR–FRET assay), which is over three orders of magnitude to Bcl-XL (Ki=48nM) and Bcl-W (Ki=245 nM). ABT-199 can disrupt BCL-2–BIM complex and induce multiple hallmarks of apoptosis, including cytochrome c release, caspase activation, the externalization of phosphatidylserine and the accumulation of sub-G0/G1 DNA, with lower concentration than ABT-263. Thus it facilitates ABT-199 to have cell-killing activity to Bcl-2 high-expressed NHL cell lines. ABT-199 can inhibit tumor xenograft growth as a single agent or combination with rituximab and bendamustine.[1]
作用机制 ABT-199 is complicated by the high degree of similarity within the BH3-binding domains of Bcl-2 and Bcl-XL.[1]

Venetoclax 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
ALL-SIL 10 μM Growth Inhibition Assay 48 h IC50=0.1803 μM 25301704
CCRF-CEM 10 μM Growth Inhibition Assay 48 h IC50=1.360 μM 24342948
CS-THL1 20 nM Growth Inhibition Assay 72 h Inhibits cell growth assessed by cell viability 25916698
CS-THL1 25 nM Apoptotic Assay Induces apoptosis 25916698

Venetoclax 动物研究

Dose Mice: max = 100 mg/kg[3]
Administration p.o.

Venetoclax 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03342144 - Recruiting December 31, 2020 Germany ... 展开 >> Onkologische Praxis /ID# 201545 Recruiting Stuttgart, Baden-Wuerttemberg, Germany, 70174 Medizinisches Versorgungszentrum (MVZ) /ID# 201548 Recruiting Aschaffenburg, Bayern, Germany, 63739 Studienzentrum Aschaffenburg /ID# 204125 Recruiting Aschaffenburg, Bayern, Germany, 63739 Praxis Dres. Hornberger & Kollegen /ID# 202613 Recruiting Bad Reichenhall, Bayern, Germany, 83435 Onkologie am Segelfliegerdamm /ID# 202603 Recruiting Berlin, Bayern, Germany, 12487 Onkologie Hof /ID# 201531 Recruiting Hof, Bayern, Germany, 95028 Praxis Dr. Vehling-Kaiser /ID# 202614 Recruiting Landshut, Bayern, Germany, 84028 Praxis Dres. Grüner/Hejazi/Niewenhuys /ID# 202602 Recruiting Weiden i.d.OPf., Bayern, Germany, 92637 Praxis Dr. Kreher /ID# 202604 Recruiting Bad Liebenwerda, Brandenburg, Germany, 04924 MVZ Dres. Cordes & Partner /ID# 202598 Recruiting Frankfurt am Main, Hessen, Germany, 60596 OAZ Hannover /ID# 201538 Recruiting Hanover, Niedersachsen, Germany, 30171 Onkolologische Praxis Oldenburg /ID# 202607 Recruiting Oldenburg, Niedersachsen, Germany, 26121 MVZ der Paracelsus-Klinik /ID# 201541 Recruiting Osnabrück, Niedersachsen, Germany, 49076 Med. Studiengesellschaft Nord West GmbH /ID# 201535 Recruiting Westerstede, Niedersachsen, Germany, 26655 Onkozentrum Dresden /ID# 202599 Recruiting Dresden, Sachsen, Germany, 01127 BAG Freiberg-Richter /ID# 201532 Recruiting Dresden, Sachsen, Germany, 01307 Onkologische Schwerpunktpraxis /ID# 200953 Recruiting Berlin, Germany, 10707 Internistische Schwerpunktprax /ID# 200949 Recruiting Erlangen, Germany, 91052 Luebecker Oncology Practice /ID# 200952 Recruiting Luebeck, Germany, 23562 Stauferklinikum Schwaebisch Gm /ID# 201518 Recruiting Mutlangen, Germany, 73557 收起 <<
NCT03112174 Mantle-Cell Lymphoma Phase 3 Recruiting September 2022 -
NCT03672695 Acute Myeloid Leukaemia Phase 1 Not yet recruiting March 31, 2022 United States, Connecticut ... 展开 >> Smilow Cancer Hospital at Yale Not yet recruiting New Haven, Connecticut, United States, 06511 United States, Texas The University of Texas MD Anderson Cancer Center, Houston, TX Not yet recruiting Houston, Texas, United States, 77030 Australia Peter MacCallum cancer centrer Not yet recruiting Melbourne, Australia The Alfred Hospital Department of Haematology Not yet recruiting Victoria Park, Australia France Institut Paoli-Calmettes Not yet recruiting Marseille, France Hopital Saint-Antoine Not yet recruiting Paris, France Institut Universitaire du Cancer Toulouse - Oncopole Not yet recruiting Toulouse, France 收起 <<

Venetoclax 参考文献

[1]Souers AJ, Leverson JD, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8.

[2]Choo EF, Boggs J, et al. The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199. Drug Metab Dispos. 2014 Feb;42(2):207-12.

[3]Punnoose EA, Leverson JD, et al. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Mol Cancer Ther. 2016 May;15(5):1132-44.

Venetoclax 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.15mL

0.23mL

0.12mL

5.76mL

1.15mL

0.58mL

11.51mL

2.30mL

1.15mL

Venetoclax 技术信息

CAS号1257044-40-8
分子式C45H50ClN7O7S
分子量 868.439
别名 ABT-199;GDC-0199;RG 7601. Venetoclax.;RG7601
运输蓝冰
存储条件

粉末 Keep in dark place,Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度

DMSO: 80 mg/mL(92.12 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

5% DMSO+50% PEG 300+5% Tween 80+water 5 mg/mL

Tags: Venetoclax | ABT-199;GDC-0199;RG 7601. Venetoclax.;RG7601 | Apoptosis | Bcl-2 | AmBeed-信号通路专用抑制剂 | Venetoclax 纯度/质量文件 | Venetoclax 亚型比较 | Venetoclax 生物活性 | Venetoclax 细胞研究 | Venetoclax 动物研究 | Venetoclax 临床数据 | Venetoclax 参考文献 | Venetoclax 实验方案 | Venetoclax 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z